PEN Stock Chart & Stats
$5560.11
$0.00(0.00%)
At close: 4:00 PM EDT
$5560.11
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4,775.70 - $5,560.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$213.94B
Enterprise Value$12.05K
Total Cash (Recent Filing)$658.79M
Total Debt (Recent Filing)$212.71M
Price to Earnings (P/E)77.7
Beta0.02
Next Earnings
Nov 04, 2026EPS Estimate
20.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.09
Shares Outstanding39,389,423
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.48
Price to Sales (P/S)8.62
P/FCF Ratio69.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6,056.82Price Target Upside8.93% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)80.54
Revenue Forecast (FY)$27.01B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionSustained revenue expansion alongside recovered operating and net margins indicates improving commercial scale and operating leverage. Strong gross margins in the mid-to-high 60% range also support continued investment in products and sales while providing resilience against cost pressure.
Robust Cash GenerationRecent operating and free cash flow growth gives Penumbra flexibility to fund research, manufacturing capacity and commercial expansion internally. Operating cash flow exceeding net income also supports the quality of reported earnings, although investment and working-capital needs absorb some cash.
Low Financial LeverageConservative financing reduces refinancing and interest-rate risk and preserves balance-sheet capacity for innovation, acquisitions or market expansion. Growing equity and assets reinforce capitalization, giving the company greater resilience if procedure demand or profitability becomes uneven.
Bears Say
Earnings VolatilityThe uneven earnings path shows that strong growth has not translated into consistently stable profitability. Future margin disruptions could arise from product investment, launch costs or operating execution, making the durability of the recent recovery an important fundamental risk.
Patent Litigation RiskThe litigation creates a structural risk to Penumbra’s recently launched thrombectomy system, potentially causing legal costs, damages, licensing expense or injunctive relief. Any restriction on commercialization could reduce the product’s contribution to future growth and market expansion.
Merger Closing UncertaintyThe approved transaction may alter Penumbra’s strategic direction and ownership structure, but unresolved closing conditions leave execution and timing uncertain. Delays, failure to close or integration requirements could distract management and affect investment priorities during the transition.
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $4775.70 and its highest was $5560.11 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $213.94B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Nov 04, 2026 which is in 54 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 30, 2026. The company reported $14.99 earnings per share for the quarter, missing the consensus estimate of $19.794 by -$4.804.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 20.51.
How many shares outstanding does Penumbra have?
Penumbra has 39,389,423 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $14.99 in its last earnings report, missing expectations of $19.794. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in MX:PEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Penumbra Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6,056.82 (8.93% Upside)
$6,056.82 (8.93% Upside)
Blogger Sentiment
Bearish
MX:PEN Sentiment 67%
Sector Average 61%
Sector Average 61%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
PEN Stock 12 Month Forecast
Average Price Target
$6,056.82
▲(8.93% Upside)










